menu
    • menu
    [{"orgOrder":0,"company":"Technophage","sponsor":"VectorB2B","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Eletriptan Hydrobromide","moa":"Serotonin 1b (5-HT1b) receptor | Serotonin 1f (5-HT1f) receptor | Serotonin 1d (5-HT1d) receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II","graph3":"Technophage","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Technophage \/ VectorB2B","highestDevelopmentStatusID":"7","companyTruncated":"Technophage \/ VectorB2B"}]

    Find Clinical Drug Pipeline Developments & Deals for Eletriptan Hydrobromide

    Menu

    Eletriptan Hydrobromide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Technophage

                            Portugal arrow
                            The MedTech Conference
                            Not Confirmed

                            Technophage

                            Portugal arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eletriptan Hydrobromide

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I/ Phase II

                            Sponsor : VectorB2B

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury

                            Details : Eletriptan HBr is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Spinal Cord Injuries.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 06, 2024

                            Lead Product(s) : Eletriptan Hydrobromide

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : VectorB2B

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Viatris

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Viatris

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eletriptan Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatrip...

                            Details : Eletriptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 21, 2013

                            Lead Product(s) : Eletriptan Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Viatris

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Viatris

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eletriptan Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study

                            Details : Eletriptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 18, 2013

                            Lead Product(s) : Eletriptan Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Viatris

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Viatris

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eletriptan Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo

                            Details : Eletriptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 18, 2013

                            Lead Product(s) : Eletriptan Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Viatris

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Viatris

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eletriptan Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine

                            Details : Eletriptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 07, 2013

                            Lead Product(s) : Eletriptan Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Viatris

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Viatris

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eletriptan Hydrobromide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study

                            Details : Eletriptan HBr is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine without Aura.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 22, 2013

                            Lead Product(s) : Eletriptan Hydrobromide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Viatris

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            Viatris

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eletriptan Hydrobromide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eletriptan Pharmacokinetics In Korean Males

                            Details : Eletriptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 08, 2010

                            Lead Product(s) : Eletriptan Hydrobromide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth